Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AMPH vs AQST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AMPH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

AMPH Overall Winner 6-Pillar Tally: AMPH 5 – 1 AQST Matrix Metrics: AMPH 9 – 1 AQST

As of Nov 20, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AMPH carries a Unified Composite Score of 48.8/100 (HOLD) at $28.25 (10.5x Forward P/E, 18.7% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin).

  • Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. AMPH 48.8/100 HOLD), AMPH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (18.7% vs. -114.1% operating margin) and revenue trajectory (+8.2% vs. -41.0% YoY).
  • Technical & Structure Timing Caution: AMPH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AMPH vs AQST
AMPH NASDAQ Head-to-Head Winner
Amphastar Pharmaceuticals, Inc.
Pharmaceutical Preparations
$28.25
+0.5% 1D
Market Cap $1.2B
TTM Revenue $746M
Forward P/E 10.5x
Beta / 30D Vol 0.07β · 37% Vol
Unified Composite Score
48.8 / 100 HOLD
Tech 38.0 Fund 46.0 Flow 67.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.3% over 20 days), RSI 54
RSI-14: 54.3 · SMA20: $28.00 · SMA50: $26.51
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.89β · 56% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $3.77 · SMA50: $4.23

6-Pillar Scorecard Institutional Category Breakdown (AMPH 5 – 1 AQST)

Columns: Metric · AMPH · AQST
1. Valuation Multiples AMPH
Forward P/E 10.5x N/M
Trailing P/E 12.9x N/M
PEG Ratio 2.77x N/M
EV / Revenue 2.3x 8.9x
2. Growth & Scale AMPH
Revenue Growth (YoY) +8.2% -41.0%
Earnings Growth (YoY) +135.1% +0.0%
TTM Revenue (USD) $746M $49M
Market Cap $1.2B $465.7M
3. Profitability & Quality AMPH
Gross Margin 46.8% 65.3%
Operating Margin 18.7% -114.1%
Net Profit Margin 13.3% -162.3%
Return on Equity (ROE) 12.4% 0.0%
4. Balance Sheet & Cash Flow AMPH
Cash Generation (TTM) $45M -$41M
Cash Flow Margin 6.0% -83.3%
Net Cash / Leverage $487M Net Debt (0.85x D/E) $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AQST
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 460.7% (100th %ile) 87.9% (64th %ile)
Put/Call OI Skew N/A 0.98x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AMPH
OpEx & R&D Intensity 28.1% of Rev ($210M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AMPH (9) vs AQST (1)
Institutional Metric AMPH AQST Criterion Row Edge
Market Capitalization
Scale
$1.2B $465.7M Larger Scale AMPH
Trailing P/E Ratio
Valuation
12.9x N/M Lower Multiple AMPH
Forward P/E Ratio
Valuation
10.5x N/M Lower Multiple AMPH
Revenue Growth (YoY)
Growth
+8.2% -41.0% Higher Growth AMPH
Operating Margin (TTM)
Profitability
18.7% -114.1% Higher Margin AMPH
Net Profit Margin
Profitability
13.3% -162.3% Higher Margin AMPH
Return on Equity (ROE)
Capital Efficiency
12.4% 0.0% Higher ROE AMPH
52-Week Range Position
Momentum
81% ($17–$31) 14% ($3–$7) Stronger Trend AMPH
Beta / 30D Volatility
Risk Regime
0.07β · 37% Vol 0.89β · 56% Vol Lower Realized Risk AMPH
Unified Institutional Score
Composite Signal
48.8 / 100 (HOLD) 62.9 / 100 (BUY) Higher Composite AQST
Trailing 12M Revenue (USD)
Operating Scale
$746M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.8% 65.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.77x PEG · 2.3x EV/Rev N/M PEG · 8.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$45M ($487M Net Debt (0.85x D/E)) -$41M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AMPH +24.71 pp
AMPH: +8.49% · AQST: -16.22%
3M Horizon AMPH +59.19 pp
AMPH: +31.27% · AQST: -27.92%
6M Horizon AMPH +69.47 pp
AMPH: +53.45% · AQST: -16.02%
1Y Horizon AMPH +52.0 pp
AMPH: +11.35% · AQST: -40.65%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period AMPH Revenue AQST Revenue AMPH Op. Margin AQST Op. Margin Margin Leader
Q3 '25 $770M $50M 13.2% -89.6% AMPH
Q4 '25 $730M $50M 19.4% -221.6% AMPH
Q1 '26 $680M $60M 8.0% -29.1% AMPH
Q2 '26 $740M $60M 21.6% -59.5% AMPH
Q3 '26 $830M $30M 24.5% -191.5% AMPH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AMPH CONSOLIDATION
39d in phase · OBV DISTRIBUTION
Current IV 460.7%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AMPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AQST BREAKDOWN
61d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 64th %ile
Put/Call OI Skew 0.98x (Balanced)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AMPH Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.2B market capitalization and 18.7% operating margin.
OpEx & R&D Reinvestment 28.1% of Rev ($210M)
90D Engineering Disclosures 0 Published
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AMPH vs AQST Key Questions & Quantitative Answers

As of Nov 20, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AMPH carries a Unified Composite Score of 48.8/100 (HOLD) at $28.25 (10.5x Forward P/E, 18.7% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin). Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. AMPH 48.8/100 HOLD), AMPH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (18.7% vs. -114.1% operating margin) and revenue trajectory (+8.2% vs. -41.0% YoY). Technical & Structure Timing Caution: AMPH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AMPH leads the Growth & Scale pillar: AMPH posts +8.2% YoY revenue growth and +135.1% YoY earnings growth on $746M TTM revenue (46.8% gross margin, 18.7% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). Across the 5-period historical trajectory (Q3 '25 to Q3 '26), AMPH cumulative revenue shifted +7.8% while AQST shifted -40.0%. In operating R&D and SG&A reinvestment, AMPH deploys 28.1% of Rev ($210M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.

AMPH screens cheaper on headline valuation multiples. AMPH trades at 10.5x Forward P/E, 12.9x Trailing P/E, 2.77x PEG, and 2.3x EV/Revenue (6.0% FCF margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMPH (12.4% ROE) versus AQST (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AMPH carries 460.7% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.07β · 37% Vol realized risk). By comparison, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.